Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model

Prostate

Volumn 66, Issue 5, 2006, Pages 495-502

  Eggener, Scott E ^a   Stern, Jeff A ^a   Jain, Pankaj M ^a   Oram, Shane ^b   Ai, Junkui ^a   Cai, Xiaoyan ^a   Roehl, Kim A ^c   Wang, Zhou ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Finasteride; Intermittent androgen ablation; LNCaP; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADOLESCENT; ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTINUOUS ANDROGEN ABLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG IMPLANT; DRUG PELLET; HORMONE ACTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; INTERMITTENT ANDROGEN ABLATION; MAINTENANCE THERAPY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MICE; MICE, NUDE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645341444     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20297     Document Type: Article

References (26)

1. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95(13):981-989.
2. De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA, Debre B. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91(1):18-22.
3. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996;58(2):139-146.
4. Pether M, Goldenberg SL, Bhagirath K, Gleave M. Intermittent androgen suppression in prostate cancer: An update of the Vancouver experience. Can J Urol 2003;10(2):1809-1814.
5. Wang Z, Tufts R, Haleem R, Cai X. Genes regulated by androgen in the rat ventral prostate. Proc Natl Acad Sci USA 1997;94(24): 12999-13004.
6. Jiang F, Wang Z. Identification of androgen-responsive genes in the rat ventral prostate by complementary deoxyribonucleic acid subtraction and microarray. Endocrinology 2003;144(4):1257-1265.
7. Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr 2001;9(4-5):183-194.
8. Oram S, Jiang F, Cai X, Haleem R, Dincer Z, Wang Z. Identification and characterization of an androgen-responsive gene encoding an aci-reductone dioxygenase-like protein in the rat prostate. Endocrinology 2004;145(4):1933- 1942.
9. Abasolo I, Yang L, Haleem R, Xiao W, Pio R, Cuttitta F, Montuenga LM, Kozlowski JM, Calvo A, Wang Z. Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo. Mol Cell Endocrinol 2003;199(1-2):179-187.
10. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003;63(15):4698-4704.
11. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
12. Zhu Y, Cai L, You X, Cordero J, Huang Y, Imperato-McGinley J. Androgen induced PSA gene expression is mediated via DHT in LNCaP cells. J Androl 2003;24:681-687.
13. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31(4):229-234.
14. Tunn U, Kurek R, Kienle E, Maubach L. Intermittent is as effective as continuous androgen depreivation in patients with PSA relapse after radical prostatectomy. American Urological Association, 2004; San Francisco, CA.
15. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5alpha-reductase. Endocrinology 1999;140(10): 4509-4515.
16. Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 1996;98(11):2558-2563.
17. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995;45(2):282-290.
18. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996;93(21): 11802-11807.
19. Wang L, Liu X, Kreis W, Budman D. Downregulation of PSA expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57(4):714-719.
20. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005;288(3):E573-E584.
21. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-540.
22. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-1398.
23. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, Calabro M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995;136(5):2309-2319.
24. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: Role for testosterone in the androgenic response. Endocrinology 1992;130(2):685-694.
25. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93(26): 15152-15157.
26. Fowler JE Jr., Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981;126(3):372-375.